GeneTex Introduces New Mouse Monoclonal Antibody Against the Ten-Eleven Translocation 1 (TET1) Protein for DNA Methylation/Epigenetics Research
IRVINE, Calif., May 8, 2013 /PRNewswire/ -- GeneTex, Inc., a leading manufacturer of antibodies and antibody-related reagents, is introducing a new mouse monoclonal antibody to the human Ten-Eleven Translocation 1 (TET1) protein. The discovery in 2009 (Tahiliani et al, 2009) that this enzyme can convert the DNA methylation mark 5-methylcytosine (5mC) to 5-hydroxymethylcytosine (5hmC) helped to usher in a new field of research in epigenetics. Since then, it has become clear that TET1 and its family members TET2 and TET3, through the oxidation of 5mC to 5hmC, 5-formylcytosine (5fC), or 5-carboxylcytosine (5caC), are pivotal factors in epigenetic signaling.
The excitement generated by the mammalian TET proteins in the last few years is due to their impact on the regulation of DNA methylation, a fundamental epigenetic mechanism that generally causes genes to be turned off through direct methylation of particular cytosines (5mC) in the DNA sequence. The enzymes responsible for this DNA methylation, termed DNA methyltransferases (DNMTs), have been identified and characterized. However, how DNA could be actively demethylated remained a puzzle. It is now thought that the TET enzymes are intimately involved in this process through the conversion of 5mC to 5hmC, 5fC, and 5caC, essentially forming a stepwise pathway to demethylation. Thus, the actions of these enzymes facilitate dynamic regulation of DNA methylation, with the readily apparent implications for development and carcinogenesis. Even more intriguing to epigenetics researchers, however, is the growing appreciation that these 5mC derivatives, in particular 5hmC, are epigenetic signals in their own right.
TET1 is known to be a challenging protein to develop quality antibodies against and GeneTex is pleased to announce a first to market mouse monoclonal TET1 antibody [GT1462] (GTX627420) that is the most extensively characterized commercially available TET1 antibody. Qualitative validation has demonstrated that this antibody can detect the human TET1 protein in ICC/IF, IHC-P, and western blot applications. Importantly, its specificity was verified by both overexpression and siRNA studies. GeneTex also produces polyclonal antibodies against TET1 as well as additional antibodies to TET2, TET3, and 5mC. For more information on GeneTex, Inc. and its products, please call toll-free 877-GENETEX (436-3839) or visit www.genetex.com.
About GeneTex, Inc.
GeneTex, Inc. is an antibody manufacturing company founded in 1997 by a group of internationally renowned academic scientists. They strive to produce the highest quality antibodies and reagents. Their primary and secondary antibodies are created through a process involving extensive research, development, and validation. GeneTex's catalog has grown to over 55,000 primary antibodies and supportive reagents, which are all backed with a 100% Satisfaction Guarantee.
We strive to serve and accelerate life science research by creating essential life science tools where quality can be found in every vial.
SOURCE GeneTex, Inc.